The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant: Post-Transplants Events

In this multicenter study, we assessed the use of palifermin (recombinant human–keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2007, Vol.40 (10), p.983-988
Hauptverfasser:	Nasilowska-Adamska, B, Rzepecki, P, Manko, J, Czyz, A, Markiewicz, M, Federowicz, I, Tomaszewska, A, Piatkowska-Jakubas, B, Wrzesien-Kus, A, Bieniaszewska, M, Duda, D, Szydlo, R, Halaburda, K, Szczepinski, A, Lange, A, Hellman, A, Robak, T, Skotnicki, A, Jedrzejczak, W W, Walewski, J, Holowiecki, J, Komarnicki, M, Dmoszynska, A, Warzocha, K, Marianska, B
Format:	Artikel
Sprache:	eng
Schlagworte:	Cell Biology Hematology Internal Medicine Medicine Medicine & Public Health original-article Public Health Stem Cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this multicenter study, we assessed the use of palifermin (recombinant human–keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 μ g/kg once daily i.v.) pre- and post-conditioning regimens (total six doses). A retrospective control group of 53 transplant patients received no palifermin. There was a significant reduction in the incidence of OM of WHO (World Health Organization) grades 1–4 (58 vs 94%, P
ISSN:	0268-3369 1476-5365
DOI:	10.1038/sj.bmt.1705846